60 results about "Platelet concentrate" patented technology

Systems and methods centrifugally separate whole blood into red blood cells, plasma, and a platelet concentrate. The systems and methods rotate a first rotating separation zone about a rotational axis, to separate whole blood into red blood cells and plasma constituent carrying platelets. Red blood cells separated are directed in a first circumferential flow direction toward a terminal wall, where blood flow is halted. Surface hematocrit is successively increased in the first circumferential flow direction by separating the plasma constituent from the red blood cells. Separated red blood cells are directed from the first rotating separation zone through a path where the surface hematocrit is the most. Plasma constituent separated is directed in a second circumferential flow direction opposite to the first circumferential flow direction toward a different region in the first rotating separation zone, where the surface hematocrit is the least. The systems and methods separate the plasma constituent into platelet concentrate and plasma in a second rotating separation zone.

An object is to provide a blood component collection system capable of collecting a desired blood component of high quality. A blood component collection system 1 comprises a centrifugal separator 20 centrifuging blood into a plurality of components, first line 21 for feeding the blood to the centrifugal separator 20, a second line 22 for releasing the blood component from the centrifugal separator 20, a temporary reservoir bag 26′ for temporarily reserving the platelet concentrate, a leukoreduction filter 261 for separating and reducing leukocyte from the platelet concentrate, and a platelet collection bag 26 for reserving the platelet concentrate having passed through the leukoreduction filter 261. The blood component collection system 1 is constructed to feed the platelet concentrate in the temporary reservoir bag 26′ to the platelet collection bag 26 through the leukoreduction filter 261, and then, feed plasma and collect the platelet remaining in the leukoreduction filter 261 (platelet concentrate from which leukocyte have been reduced) together with the plasma into the platelet collection bag 26.

Methods of detecting bacterial contamination in a platelet concentrate are performed using a dynamic light scattering (DLS) instrument and a sample holder. A sample of platelet concentrate can be held vertically or horizontally in a capillary in the sample holder. Alternatively, novel platelet storage bags modified to include an optically translucent window can be held within another variant of the sample holder. Still alternatively, platelet storage bags having one or more tubes detachably appended to the bag can be used. A sample is drawn off into an appended tube for placement directly into the sample holder. This method provides a number of related, non-invasive techniques for detecting whether bacteria has contaminated a platelet concentrate. Contamination indicators include a population of particles different from platelets, microparticles or proteins, bad-quality platelets, i.e. low DLS score, and very high or very low scattering intensity.

Platelet suspensions and methods for resuspending platelet concentrates are disclosed. The platelet concentrates are resuspended by combining a platelet concentrate with a substance capable of resuspending platelets, such as a salt solution. The resuspended platelets may be stored and / or administered to a patient.

The present invention is related to the field of tissue regeneration. It concerns more particularly new processes, tubes and devices for thrombin, platelet concentrate and wound healant preparations, alone or in combination with cell extracts, cell compositions and uses thereof.

A process is disclosed for preparing an autologous platelet gel and membranes thereof comprising mixing a platelet concentrate with a calcium salt and batroxobin. This process encompassing the use of batroxobin as the gel activator allows to overcome the prior art processes drawbacks connected with the use for the same purpose of human of bovine thrombin. A kit is also described for carrying out this process.

Automated systems and methods for providing platelet concentrates and synthetic storage media with reduced residual plasma volumes are disclosed. The disclosed systems and methods reduce the residual volume of plasma in platelet concentrate to obtain a platelet product having a volume of plasma that is approximately 5% or less of the total platelet product volume. The disclosed systems and methods also reduce the residual volume of plasma in platelet concentrate to obtain a washed platelet product, wherein the volume of plasma in the washed platelet product is approximately 1% or less of the total washed platelet product volume. Storage media for platelets including less than approximately 10% plasma are also disclosed.

Described are systems, methods, and kits for compression sedimentation and whole blood separation. For example, a compression sedimentation system may include a compression stage configured to accept a flexible reservoir configured to contain a liquid mixture. The compression stage may include a base substrate and a compression substrate configured to apply a force to the flexible reservoir effective to create a pressure in the liquid mixture. An apparatus for whole blood separation may include a sedimentation system that separates whole blood into a supernatant including platelet rich plasma and a subnatant including red blood cells. At least one platelet-concentrating device may be included to receive the supernatant including the PRP and to separate a platelet concentrate and a platelet poor plasma from the supernatant.

Provides are improved methods for storing platelets and compositions that contain stored platelets for use in transfusions. The method entails obtaining a platelet concentrate from blood obtained from an individual and holding the platelet concentrate in at refrigerated temperatures under an atmosphere having a pressure of from 3.5 to 5 bars comprising more than 65% xenon and for at least one week. Also provided is a refrigerated composition that contains a platelet concentrate, wherein the platelet concentrate contains xenon, and wherein the platelet concentrate has been isolated from an individual for at least seven days.

The present disclosure relates to a clottable concentrate of platelet growth factors for therapeutic and / or cosmetic use, preferably comprising the growth factors PDGF, TGT-β, IGF, EGF, CTGF, bFGF and VEGF. In a preferred embodiment, the clottable concentrate of platelet growth factors does not induce blood cell-related transfusion reactions. The present disclosure also relates to a method for preparing a clottable concentrate of platelet growth factors including the steps of contacting a platelet concentrate with a solvent and / or a detergent, incubating the platelet concentrate with the solvent and / or detergent for a period of at least 5 minutes to 6 hours, at a pH maintained in a range from about 6.0 to about 9.0, and at a temperature within the range of from 2° C. to 50° C., preferably within the range of from 25° C. to 45° C., and removing the solvent and / or the detergent by oil extraction and / or chromatographic means.

The present invention is related to the field of tissue regeneration. It concerns more particularly new processes, tubes and devices for thrombin, platelet concentrate and wound healant preparations, alone or in combination with cell extracts, cell compositions and uses thereof.

A method for more effectively concentrating blood platelets for use in medical procedures includes providing preparation and concentrating tubes. Anticoagulated whole blood is added to the preparation tube, which is centrifuged to separate red blood cells from a platelet plasma suspension The platelet plasma suspension is aspirated and loaded into the concentrating tube, which is itself centrifuged to separate the platelet plasma suspension into platelet poor plasma and platelet rich plasma layers. The platelet poor plasma is aspirated through a port of the concentrating tube and the remaining concentrated PRP is aspirated through the same or a different port of the concentrating tube.

An improved anticoagulant is based on a higher level of citric acid than is usual (at least about 0.2% weight by volume). The higher citrate is combined with an amino acid as a counterion. The amino acid prevents cellular damage often caused by elevated citrate levels. The amino acid citrate mixture also serves to preserve platelet concentrates and platelet rich plasma during room incubation. Not only does the amino acid citrate combination enhance platelet integrity, it completely inhibits the growth of bacteria such as Staphylococcus epidermidis. Collecting blood of plasma into such higher levels of citrate prevents activation of blood proteins so that fractions made from the blood or plasma have superior characteristics.

A method and a platelet concentrate preservation device for platelet concentrate storage. A method includes at least partially saturating platelet concentrate xenon, and storing the platelet concentrate at less than 15 C in a generally horizontal position. A device can be used to store blood, blood products, or combinations thereof that may or may not be under pressure. The device includes a chamber having a cavity. The chamber includes first and second chamber parts that form the cavity when releasably connected together. The cavity is designed to receive at least one bag that contains the blood, blood products, or combinations thereof. The device also includes a high-strength casing and includes a chamber cavity. The high-strength casing includes first and second casing parts that form the chamber cavity when releasably connected together. The chamber cavity is designed to receive the chamber.